Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zogenix Inc (NQ: ZGNX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zogenix Inc

< Previous 1 2 Next >
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
Merger Arbitrage Mondays - Healthcare Trust Of America To Combine With Healthcare Realty Trust
Merger activity increased last week with six new deals announced and six deals completed. Three of the six new deals announced were potential deals in the works. Healthcare Trust... 
Via Benzinga
Recap: Zogenix Q4 Earnings
Zogenix (NASDAQ:ZGNX) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that... 
Via Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles 150 Points; Yumanity Therapeutics Shares Plunge
Toward the end of trading Wednesday, the Dow traded down 0.45% to 35,210.04 while the NASDAQ fell 0.28% to 14,466.47. The S&P also fell, dropping, 0.29% to 4,563.94. The U.S.... 
Via Benzinga
SBEV Stock: The Ralph’s Grocery Deal Making Waves for Splash Beverage Group Today
Splash Beverage (SBEV) stock is soaring higher on Wednesday after the company revealed a new deal bringing its drinks to additional stores. 
Via InvestorPlace
52 Biggest Movers From Yesterday
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion. G... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Zogenix (NASDAQ:ZGNX) shares moved upwards by 67.2% to $26.15 during Wednesday's regular session. As of 12:30 EST, Zogenix's stock is trading at a volume... 
Via Benzinga
Mid-Day Market Update: US Stocks Turn Negative; Zogenix Shares Spike Higher
Midway through trading Wednesday, the Dow traded down 0.13% to 35,321.51 while the NASDAQ fell 0.53% to 14,430.41. The S&P also fell, dropping, 0.19% to 4,568.33. The U.S. has... 
Via Benzinga
GENI Stock: The Analyst Call Sending Genius Sports Shares Surging Today
Genius Sports (GENI) stock is on the rise Wednesday after an analyst initiated coverage of the sports data and tech company. 
Via InvestorPlace
35 Stocks Moving In Wednesday's Mid-Day Session
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares jumped 67.1% to $26.15 after the company announced it will be acquired by UCB for approximately $1.9 billion. Splash Beverage Group,... 
Via Benzinga
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal. 
Via InvestorPlace
Mid-Morning Market Update: Markets Rise; Bank of America Posts Upbeat Profit
Following the market opening Wednesday, the Dow traded up 0.12% to 35,411.14 while the NASDAQ rose 0.90% to 14,638.13. The S&P also rose, gaining, 0.44% to 4,597.47. The U.S.... 
Via Benzinga
Zogenix Nabs $1.9 Billion Takeover As Epilepsy Drug Piques UCB Interest
The deal includes a CVS tied to Fintepla's next potential approval. 
Via Investor's Business Daily
Why Zogenix Shares Are Soaring Today
Zogenix Inc (NASDAQ: ZGNX) is trading significantly higher Wednesday morning after the company announced it received a proposal to be acquired by UCB for approximately $... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Zogenix (NASDAQ:ZGNX) stock rose 68.2% to $26.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.4 billion. Lucid... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investor! We're diving right into trading today with a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares rose 56.1% to $24.41 in pre-market trading after UCB announced plans to acquire the company. Fresh Vine Wine, Inc. (NYSE: VINE) rose... 
Via Benzinga
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion,... 
Via Benzinga
Why Are Zogenix's Shares Gaining Today?
The FDA has granted Priority Review to Zogenix Inc's (NASDAQ: ZGNX) supplemental marketing application seeking approval for Fintepla (fenfluramine) in... 
Via Benzinga
Exposures Product Safety
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Recap: Zogenix Q3 Earnings
Zogenix (NASDAQ:ZGNX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Zogenix... 
Via Benzinga
Zogenix Earnings Preview
Zogenix (NASDAQ:ZGNX) is set to give its latest quarterly earnings report on Thursday, 2021-11-04. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.